investigators news from FierceBioResearcher
News
Geron: Stem cells repair heart attack damage
Common virus is a culprit in obesity
First gene therapy for eye disease may offer a cure
Robin Ali, a professor of human molecular genetics at University College London, is leading the world's first human trial of a gene therapy for an eye condition. A total of 12 patients with Leber's Congenital Amaurocis are being treated in the trial. Their photoreceptor cells misfunction due to a faulty RPE65 gene. That is an extremely rare condition, but investigators say that if this trial works they'll be able to use a similar approach to treating about 100 single-gene sight disorders …
Read more...Number of minority researchers at NIH drops
Minorities may suffer disproportionately from a wide number of afflictions, but they are noticeably lacking among the ranks of the top research groups in the country. According to a recent survey, blacks make up 1 percent of the tenured and tenure-track researchers at the country's top 50 academic research centers. And that performance is reflected at the NIH, according to a …
Read more...New study to use stem cells after heart attacks
Doctors in the UK are preparing to begin a study to see whether injecting stem cells harvested from a patient's bone marrow can repair the damage on heart muscle inflicted by a heart attack. The injections will be given within five hours of a heart attack, a critical period in the eyes of investigators. Doctors will recruit 100 patients for the procedure, which will also include angioplasty to clear blocked arteries--a standard therapy in these cases. Earlier studies have demonstrated …
Read more...Get more investigators coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight

